Cetuximab and erlotinib are effective in treating advanced cSCC by inhibiting the activity of the epidermal growth factor receptor, which is often overexpressed in cSCC tumors (Chang et al., 2023[37]). The gene discussed is EGFR; the disease is skin squamous cell carcinoma.